PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Net income growth exceeding 1.5x Healthcare median of 2.35%. Joel Greenblatt would see it as a clear outperformance relative to peers.
3.87%
D&A growth of 3.87% while Healthcare median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
17.23%
Deferred tax growth of 17.23% while Healthcare median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-49.98%
SBC declines yoy while Healthcare median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
93.54%
Working capital of 93.54% while Healthcare median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
AP growth of 48.23% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
21.18%
Growth of 21.18% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-49.98%
Other non-cash items dropping yoy while Healthcare median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
33.57%
CFO growth of 33.57% while Healthcare median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-2609.70%
CapEx declines yoy while Healthcare median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
Reduced investing yoy while Healthcare median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
5.36%
Debt repayment growth of 5.36% while Healthcare median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
-80.40%
We reduce issuance yoy while Healthcare median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.